Q-122: Phase Ib data

The open-label, U.S. Phase Ib Study Q-1001 in 21 female patients with breast cancer who were receiving an aromatase inhibitor or tamoxifen showed that once-daily 100 and 200 mg oral Q-122 for 28 days...